Government-Owned Inventions; Availability for Licensing, 59039-59040 [2013-23231]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 186 / Wednesday, September 25, 2013 / Notices
Act of 1995 (44 U.S.C. 3501–3520). The
collections of information in 21 CFR
part 801 are approved under OMB
control number 0910–0485; the
collection of information in 21 CFR part
803 are approved under OMB control
number 0910–0437; the collections of
information in 21 CFR part 806 are
approved under OMB control number
0910–0359; the collections of
information in 21 CFR part 807 Subpart
B are approved under OMB control
number 0910–0387; the collections of
information in 21 CFR part 807 Subpart
E are approved under OMB control
number 0910–0120; the collections of
information in 21 CFR part 814 Subparts
B and E are approved under OMB
control number 0910–0231; and the
collections of information in 21 CFR
part 820 are approved under OMB
control number 0910–0073.
V. Comments
Interested persons may submit either
electronic comments regarding this
document to https://www.regulations.gov
or written comments to the Division of
Dockets Management (see ADDRESSES). It
is only necessary to send one set of
comments. Identify comments with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday, and
will be posted to the docket at https://
www.regulations.gov.
Dated: September 19, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–23293 Filed 9–24–13; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR Part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:20 Sep 24, 2013
Jkt 229001
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Small Interfering RNA Knock-Down of
Cannabinoid-1 Receptor (CB1R) for the
Treatment or Prevention of Type-2
Diabetes
Description of Technology:
Endocannabinoids (EC) are lipid
signaling molecules that act on the same
cannabinoid receptors that recognize
and mediate the effects of marijuana.
Activation of the EC receptor CB1R has
been shown to play a key role in the
development of obesity and its
metabolic consequences, including
insulin resistance and type 2 diabetes.
Researchers at NIH have now
demonstrated in the Zucker diabetic
fatty (ZDF) rat model of type-2 diabetes
that beta-cell loss is caused by the
CB1R-mediated activation of a
macrophage-mediated inflammatory
response. They have further
demonstrated that treatment of ZDF rats
with a peripheral CB1R antagonist
restores normoglycemia and preserves
beta-cell function and that similar
results were seen following selective in
vivo knockdown of macrophage CB1R
by daily treatment of ZDF rats with Dglucan-encapsulated CB1R Small
interfering RNA (siRNA). Therefore,
knock-down of CB1R with siRNA may
represent a new method of treating type2 diabetes or preventing the progression
of insulin resistance to overt diabetes.
Potential Commercial Applications:
Treatment of obesity, insulin resistance,
and diabetes.
Competitive Advantages: A new
means of inhibiting the
endocannabinoid receptor CB1R.
Development Stage: In vivo data
available (animal).
Inventors: George Kunos (NIAAA),
Tony Jourdan (NIAAA), Michael P.
Czech (UMass Medical School), Myriam
Aouadi (UMass Medical School).
Intellectual Property: HHS Reference
No. E–103–2013/0—US Application No.
61/839,239 filed June 25, 2013.
Licensing Contact: Jaime M. Greene;
301–435–5559; greenejaime@
mail.nih.gov.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
59039
Methods for the Treatment of AIDS and
Other Retroviral Diseases Using PlantDerived Compounds
Description of Technology: Human
immunodeficiency virus-1 (HIV–1)
affects 1.4 million patients in the U.S.
and over 33 million worldwide. While
highly active antiretroviral therapy
(HAART), the current standard of care,
is effective in suppressing retroviral
activity, cure has not been achieved due
to the persistence of latently infected T
cells in treated patients. An agent
capable of sensitizing this T cell
subpopulation concordant with HAART
may add significant benefit to
individuals with retroviral diseases.
Researchers at the NIH have identified
Englerin A and its derivatives as potent
and specific activators of viral
replication in infected T cells. Use of
these compounds in conjunction with
existing antiviral therapies has been
described for the treatment of AIDS,
adult T cell leukemia/lymphoma and
other retroviral diseases.
Intellectual property assets available
for license include novel compositions
of Englerin A along with methods of
their use in the treatment of retroviral
diseases.
Potential Commercial Applications
• Novel adjuvant therapy for the
treatment of retroviral diseases such as
AIDS or HTLV-induced leukemia/
lymphoma.
• Therapeutic for the management of
T lymphocytopenia.
Competitive Advantages
• Englerin A and its derivatives are
potent and selective activator of protein
kinase C theta in immune cells.
• Compounds are anticipated to have
fewer off-target toxicities relative to
currently available PKC activators (e.g.,
interleukins-2 and 7).
• Compounds are optimized for use
in combination with clinically available
antiviral agents.
Development Stage
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: Leonard Neckers, Marston
Lineham, Carole Sourbier, Jane Trepel,
Min-jung Lee, Bradley Scroggins, John
Beutler (all of NCI).
Publications
1. Ratnayake R, et al. Englerin A, a
selective inhibitor of renal cancer cell
growth, from Phyllanthus engleri. Org
Lett. 2009 Jan 1;11(1):57–60. [PMID
19061394].
E:\FR\FM\25SEN1.SGM
25SEN1
59040
Federal Register / Vol. 78, No. 186 / Wednesday, September 25, 2013 / Notices
2. Li Z et al. A brief synthesis of (-)englerin A. J Am Chem Soc. 2011 May
4;133(17):6553–6. [PMID 21476574].
3. Akee R, et al. Chlorinated englerins
with selective inhibition of renal cancer
cell growth. J Nat Prod. 2012 Mar
23;75(3):459–63. [PMID 22280462].
4. Sourbier C, et al. Englerin A
stimulates PKC theta to inhibit insulin
signaling and to simultaneously activate
HSF1: pharmacologically induced
synthetic lethality. Cancer Cell. 2013
Feb 11;23(2):228–37. [PMID 23352416].
Intellectual Property: HHS Reference
No. E–201–2012/0—US Application No.
61/726,975 filed November 15, 2012.
Related Technologies
• HHS Reference No. E–064–2008—
‘‘Englerin A: A Novel Renal Cancer
Therapeutic Isolated from an African
Plant.’’
• HHS Reference No. E–042–2012—
‘‘Use of Englerin A for the Treatment of
Diabetes, Obesity and Other Diseases.’’
Licensing Contact: Surekha Vathyam,
Ph.D.; 301–435–4076; vathyams@
mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute Molecular
Targets Development Program is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize epoxy-guaiane
derivatives for retroviral therapy. For
collaboration opportunities, please
contact John D. Hewes, Ph.D. at hewesj@
mail.nih.gov.
mstockstill on DSK4VPTVN1PROD with NOTICES
Development of Immune System
Tolerance for the Treatment of
Autoimmune Disease
Description of Technology: The
present invention provides a therapeutic
method for the treatment of
autoimmune or autoinflammatory
diseases by first breaking down the
dysregulated immune system and then
reprogramming the immune system to
restore tolerance to the patient’s selfantigens by induction of antigen specific
regulatory T cells. The inventors have
shown that only with the combination
of apoptosis, phagocytes, and antigen
can antigen-specific regulatory T cells
(Treg) cells be optimally generated to
develop long-term immune tolerance.
This strategy for developing immune
tolerance can be applied to the
treatment of autoimmune diseases.
Potential Commercial Applications:
Treatment of autoimmune disease.
Competitive Advantages: This
technology represents a novel means of
treating autoimmune disease.
Development Stage
• Early-stage.
VerDate Mar<15>2010
17:20 Sep 24, 2013
Jkt 229001
• In vivo data available (animal).
Inventors: Wanjun Chen (NIDCR),
Shimpei Kassagi, Pin Zhang.
Intellectual Property: HHS Reference
No. E–186–2009/0—US Provisional
Application No. 61/844,564 filed July
10, 2013.
Licensing Contact: Jaime M. Greene;
301–435–5559; greenejaime@
mail.nih.gov.
Dated: September 19, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–23231 Filed 9–24–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; MIDAS Review Meeting.
Date: October 11, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Brian R. Pike, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3An.18K, Bethesda, MD
20892–4874, 301–594–3607,
pikbr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Dated: September 19, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–23210 Filed 9–24–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Tobacco Control Regulatory Research.
Date: October 15–16, 2013.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: St. Gregory Hotel, 2033 M Street,
NW., Washington, DC 20036.
Contact Person: Mark P Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1775, rubertm@csr.nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group, Drug Discovery for the
Nervous System Study Section.
Date: October 17, 2013.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Pier 5 Hotel, 711 Eastern Avenue,
Baltimore, MD 21202.
Contact Person: Mary Custer, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4148,
MSC 7850, Bethesda, MD 20892, (301) 435–
1164, custerm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Academic
Research Enhancement Award.
Date: October 18, 2013.
Time: 8:00 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
E:\FR\FM\25SEN1.SGM
25SEN1
]]>Agencies
[Federal Register Volume 78, Number 186 (Wednesday, September 25, 2013)]
[Notices]
[Pages 59039-59040]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-23231]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR Part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Small Interfering RNA Knock-Down of Cannabinoid-1 Receptor (CB1R) for
the Treatment or Prevention of Type-2 Diabetes
Description of Technology: Endocannabinoids (EC) are lipid
signaling molecules that act on the same cannabinoid receptors that
recognize and mediate the effects of marijuana. Activation of the EC
receptor CB1R has been shown to play a key role in the development of
obesity and its metabolic consequences, including insulin resistance
and type 2 diabetes. Researchers at NIH have now demonstrated in the
Zucker diabetic fatty (ZDF) rat model of type-2 diabetes that beta-cell
loss is caused by the CB1R-mediated activation of a macrophage-mediated
inflammatory response. They have further demonstrated that treatment of
ZDF rats with a peripheral CB1R antagonist restores normoglycemia and
preserves beta-cell function and that similar results were seen
following selective in vivo knockdown of macrophage CB1R by daily
treatment of ZDF rats with D-glucan-encapsulated CB1R Small interfering
RNA (siRNA). Therefore, knock-down of CB1R with siRNA may represent a
new method of treating type-2 diabetes or preventing the progression of
insulin resistance to overt diabetes.
Potential Commercial Applications: Treatment of obesity, insulin
resistance, and diabetes.
Competitive Advantages: A new means of inhibiting the
endocannabinoid receptor CB1R.
Development Stage: In vivo data available (animal).
Inventors: George Kunos (NIAAA), Tony Jourdan (NIAAA), Michael P.
Czech (UMass Medical School), Myriam Aouadi (UMass Medical School).
Intellectual Property: HHS Reference No. E-103-2013/0--US
Application No. 61/839,239 filed June 25, 2013.
Licensing Contact: Jaime M. Greene; 301-435-5559;
greenejaime@mail.nih.gov.
Methods for the Treatment of AIDS and Other Retroviral Diseases Using
Plant-Derived Compounds
Description of Technology: Human immunodeficiency virus-1 (HIV-1)
affects 1.4 million patients in the U.S. and over 33 million worldwide.
While highly active antiretroviral therapy (HAART), the current
standard of care, is effective in suppressing retroviral activity, cure
has not been achieved due to the persistence of latently infected T
cells in treated patients. An agent capable of sensitizing this T cell
subpopulation concordant with HAART may add significant benefit to
individuals with retroviral diseases.
Researchers at the NIH have identified Englerin A and its
derivatives as potent and specific activators of viral replication in
infected T cells. Use of these compounds in conjunction with existing
antiviral therapies has been described for the treatment of AIDS, adult
T cell leukemia/lymphoma and other retroviral diseases.
Intellectual property assets available for license include novel
compositions of Englerin A along with methods of their use in the
treatment of retroviral diseases.
Potential Commercial Applications
Novel adjuvant therapy for the treatment of retroviral
diseases such as AIDS or HTLV-induced leukemia/lymphoma.
Therapeutic for the management of T lymphocytopenia.
Competitive Advantages
Englerin A and its derivatives are potent and selective
activator of protein kinase C theta in immune cells.
Compounds are anticipated to have fewer off-target
toxicities relative to currently available PKC activators (e.g.,
interleukins-2 and 7).
Compounds are optimized for use in combination with
clinically available antiviral agents.
Development Stage
Pre-clinical.
In vitro data available.
In vivo data available (animal).
Inventors: Leonard Neckers, Marston Lineham, Carole Sourbier, Jane
Trepel, Min-jung Lee, Bradley Scroggins, John Beutler (all of NCI).
Publications
1. Ratnayake R, et al. Englerin A, a selective inhibitor of renal
cancer cell growth, from Phyllanthus engleri. Org Lett. 2009 Jan
1;11(1):57-60. [PMID 19061394].
[[Page 59040]]
2. Li Z et al. A brief synthesis of (-)-englerin A. J Am Chem Soc.
2011 May 4;133(17):6553-6. [PMID 21476574].
3. Akee R, et al. Chlorinated englerins with selective inhibition
of renal cancer cell growth. J Nat Prod. 2012 Mar 23;75(3):459-63.
[PMID 22280462].
4. Sourbier C, et al. Englerin A stimulates PKC theta to inhibit
insulin signaling and to simultaneously activate HSF1:
pharmacologically induced synthetic lethality. Cancer Cell. 2013 Feb
11;23(2):228-37. [PMID 23352416].
Intellectual Property: HHS Reference No. E-201-2012/0--US
Application No. 61/726,975 filed November 15, 2012.
Related Technologies
HHS Reference No. E-064-2008--``Englerin A: A Novel Renal
Cancer Therapeutic Isolated from an African Plant.''
HHS Reference No. E-042-2012--``Use of Englerin A for the
Treatment of Diabetes, Obesity and Other Diseases.''
Licensing Contact: Surekha Vathyam, Ph.D.; 301-435-4076;
vathyams@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
Molecular Targets Development Program is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate or commercialize epoxy-guaiane
derivatives for retroviral therapy. For collaboration opportunities,
please contact John D. Hewes, Ph.D. at hewesj@mail.nih.gov.
Development of Immune System Tolerance for the Treatment of Autoimmune
Disease
Description of Technology: The present invention provides a
therapeutic method for the treatment of autoimmune or autoinflammatory
diseases by first breaking down the dysregulated immune system and then
reprogramming the immune system to restore tolerance to the patient's
self-antigens by induction of antigen specific regulatory T cells. The
inventors have shown that only with the combination of apoptosis,
phagocytes, and antigen can antigen-specific regulatory T cells
(Treg) cells be optimally generated to develop long-term
immune tolerance. This strategy for developing immune tolerance can be
applied to the treatment of autoimmune diseases.
Potential Commercial Applications: Treatment of autoimmune disease.
Competitive Advantages: This technology represents a novel means of
treating autoimmune disease.
Development Stage
Early-stage.
In vivo data available (animal).
Inventors: Wanjun Chen (NIDCR), Shimpei Kassagi, Pin Zhang.
Intellectual Property: HHS Reference No. E-186-2009/0--US
Provisional Application No. 61/844,564 filed July 10, 2013.
Licensing Contact: Jaime M. Greene; 301-435-5559;
greenejaime@mail.nih.gov.
Dated: September 19, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-23231 Filed 9-24-13; 8:45 am]
BILLING CODE 4140-01-P
